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Volume xAvailable online XXXBackground: Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and
human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not
been compared with that of chemotherapy in a phase III trial.
Patients and methods: PEARL is a multicentre, phase III randomised study in which patients with aromatase inhibitor
(AI)-resistant MBC were included in two consecutive cohorts. In cohort 1, patients were randomised 1 : 1 to palbociclib
plus exemestane or capecitabine. On discovering new evidence about estrogen receptor-1 (ESR1) mutations inducing
resistance to AIs, the trial was amended to include cohort 2, in which patients were randomised 1 : 1 between
palbociclib plus fulvestrant and capecitabine. The stratification criteria were disease site, prior sensitivity to ET, prior
chemotherapy for MBC, and country of origin. Co-primary endpoints were progression-free survival (PFS) in cohort 2
and in wild-type ESR1 patients (cohort 1 þ cohort 2). ESR1 hotspot mutations were analysed in baseline circulating
tumour DNA.
Results: From March 2014 to July 2018, 296 and 305 patients were included in cohort 1 and cohort 2, respectively.
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hazard ratio (aHR): 1.13; 95% confidence interval (CI): 0.85-1.50] and wild-type ESR1 patients (median PFS: 8.0 versus
10.6 months; aHR: 1.11; 95% CI: 0.87-1.41). The most frequent grade 3-4 toxicities with palbociclib plus exemestane,
palbociclib plus fulvestrant and capecitabine, respectively, were neutropenia (57.4%, 55.7% and 5.5%), hand/foot
syndrome (0%, 0% and 23.5%), and diarrhoea (1.3%, 1.3% and 7.6%). Palbociclib plus ET offered better quality of
life (aHR for time to deterioration of global health status: 0.67; 95% CI: 0.53-0.85).
Conclusions: There was no statistical superiority of palbociclib plus ET over capecitabine with respect to PFS in MBC
patients resistant to AIs. Palbociclib plus ET showed a better safety profile and improved quality of life.
Key words: palbociclib, capecitabine, metastatic breast cancer, hormone receptor-positive, HER2-negative, endocrine
therapyINTRODUCTION
Until recently, single-agent endocrine therapy (ET) was the
recommended choice of treatment of most women with
hormone receptor-positive and human epidermal growth
factor receptor 2 (HER2)-negative metastatic breast cancer
(MBC). Unfortunately, not all patients respond to ET due to
primary or acquired resistance. In the past decade, new
targeted therapies, mainly cyclin-dependent kinase 4/6
(CDK4/6) inhibitors, in combination with ET have signifi-
cantly improved progression-free survival (PFS)1-7 and
overall survival (OS)8-10 compared with ET alone in patients
with treatment-naive or pretreated MBC.
The PALOMA-3 trial4 showed that palbociclib plus ful-
vestrant significantly improved PFS as opposed to fulves-
trant plus placebo [hazard ratio (HR): 0.46; P < 0.0001] in
patients who experienced cancer relapse or progression
during or within 12 months of completing adjuvant ET or
while they were on ET or within 1 month of prior ET for
MBC. Consequently, palbociclib plus fulvestrant was
approved by the Food and Drug Administration and the
European Medicines Agency for these patients. That trial
showed that adding palbociclib to fulvestrant significantly
delayed disease progression compared with fulvestrant
alone in patients resistant to aromatase inhibitors (AIs).
However, we still considered it necessary to analyse the
efficacy differences between palbociclib plus ET and other
current standards of care in MBC patients resistant to AIs,
such as chemotherapy.
In 2014, the GEICAM Spanish Breast Cancer Group star-
ted the PEARL trial in collaboration with the Central Euro-
pean Cooperative Oncology Group (CECOG). This trial
compared palbociclib plus ET with capecitabine in a popu-
lation of postmenopausal patients very similar to those in
the PALOMA-3 trial. We selected capecitabine as the
chemotherapy agent as it is considered to be one of the
most active drugs available for MBC, with median PFS
ranging from 2.8 to 5.9 months (which was even higher in
patients with hormone receptor-positive disease) and OS
times of 9.3-18.1 months in previously treated MBC pa-
tients.11-14 We combined palbociclib with exemestane in
the initial study design; however, after the emerging evi-
dence that patients pretreated with AIs may develop ESR1
mutations that generate resistance to AIs, we introduced a
second cohort in which palbociclib was combined with
fulvestrant.15,16https://doi.org/10.1016/j.annonc.2020.12.013METHODS
Study design
The PEARL trial (clinical trial registration number: ClinTrials.
gov reference NCT02028507), a multicentre, international,
open-label, controlled, randomised phase III study with two
successive cohorts of similar characteristics, was carried out
in four countries (37 sites): Spain (GEICAM), Austria,
Hungary, and Israel (CECOG). Cohort 1 patients were
randomised 1 : 1 to receive palbociclib (125 mg/day for 3
weeks followed by 1 week off) plus exemestane (25 mg/
day) or capecitabine [according to the approved label: 2500
mg/m2/day (2000 mg/m2/day in patients aged >70 years
old) for 2 weeks followed by 1 week off]. The study hy-
pothesis endorsed the superiority of palbociclib plus
exemestane over capecitabine (expected PFS, HR: 0.686,
with a 5% significance level). In December 2015, new data
suggested that exemestane in patients who have pro-
gressed on AIs could be a suboptimal option because ESR1
mutations may confer AI therapy resistance in patients
previously exposed to AIs (with a frequency of mutations of
29%-37%).15-17 One of the studies suggested that fulves-
trant may be effective in patients with ESR1 mutation-
positive tumours.16 In May 2016, a protocol amendment
with a modification of trial design and objectives was
approved before any efficacy data were available. Therefore,
a subsequent cohort 2 was introduced, in which patients
were randomised 1 : 1 to receive palbociclib (same schedule
as cohort 1) plus fulvestrant (500 mg intramuscular injec-
tion on days 1 and 15 of cycle 1; then on day 1 of subse-
quent 28-day cycles) or capecitabine (same schedule as
cohort 1). At that time, 296 patients were already recruited
in cohort 1 (from an initial planned sample of 348 patients).
The new study hypotheses endorsed the superiority of
palbociclib plus fulvestrant over capecitabine and palboci-
clib plus ET over capecitabine in patients with wild-type
ESR1 (expected PFS, HR: 0.667, with a 5% significance
level) (Supplementary Material S1, available at https://doi.
org/10.1016/j.annonc.2020.12.013).
Randomisation was carried out centrally at the GEICAM
headquarters. In both the cohorts, stratification criteria
were disease site (visceral/non-visceral), sensitivity to prior
ET [relapse after 24 months of adjuvant ET or response
(complete or partial) or stabilisation after 24 weeks of the
most recent ET in the context of advanced disease (yes/Volume xxx - Issue xxx - 2021
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origin. The treatment continued until either objective dis-
ease progression, according to the RECIST v1.1,18 symp-
tomatic deterioration, unacceptable toxicity, death, or
withdrawal of consent, whichever occurred first. As-per-
protocol dose reductions of palbociclib and capecitabine
were allowed in case of toxicity. Upon completion of the
study treatment, patients were monitored for survival every
6 months.
Research protocol was approved by every site’s institu-
tional review board and every country’s regulatory agency.
All the patients signed written informed consents. Safety
and efficacy data were continuously evaluated by an inde-
pendent data monitoring committee. The data were ana-
lysed by a statistician employed by GEICAM.Patients
Postmenopausal women with hormone receptor-positive
and HER2-negative AI-resistant MBC (defined as recur-
rence: while on or within 12 months after the end of
adjuvant treatment or progression; while on or within 1
month after the end of treatment of advanced disease)
were included. Patients had to have measurable disease
assessable by computed tomography (CT)/magnetic imaging
resonance (MRI) according to RECIST v1.1 or at least one
lytic or mixed bone lesion. One chemotherapy line for MBC
was permitted. Additional inclusion criteria included Eastern
Cooperative Oncology Group performance status (ECOG) of
0 or 1, life expectancy of 12 weeks or more, and adequate
organ function.
Patients who received prior treatment with CDK4/6,
mammalian target of rapamycin (mTOR) or phosphoinosi-
tide 3-kinase (PI3K) inhibitors, capecitabine, or patients with
visceral crisis were excluded. Patients were required to have
a corrected QT interval (QTc) <480 ms and no family or
personal history of long or short QT syndrome, Brugada
syndrome, Torsade de Pointes, or known history of QTc
prolongation.Trial assessments
Baseline disease assessments (carried out within 4 weeks
before randomisation), required a CT or MRI scan of the
chest, abdomen, and pelvis. Assessments were carried out
every 8 weeks for 120 weeks and then every 12 weeks until
documented progressive disease, initiation of a new anti-
cancer therapy, or patient dropout. Patients who dis-
continued study treatment for reasons other than
progressive disease had tumour assessments every 12
weeks.
Haematology and biochemistry tests were carried out
before each cycle; haematology testing was additionally
carried out on day 14 of cycles 1 and 2 in the palbociclib
arms. Adverse events (AEs) were assessed and graded at
each cycle according to National Cancer Institute common
terminology criteria for adverse events (NCI-CTCAE) version
4.0.Volume xxx - Issue xxx - 2021Patients completed the European Organization for
Research and Treatment of Cancer core quality-of-life
(EORTC QLQ-C30; v3.0),19 BC-specific (EORTC QLQ-BR23;
v1.0),20 and the EuroQoL Health Utilities Index EQ-5D-3L21
questionnaires at baseline, at every two cycles for the
first seven cycles, then at every three cycles until the end of
treatment, and once again at the visit after treatment.
Patients were required to have a mandatory plasma
sample drawn for exploratory biomarker analyses in circu-
lating tumour DNA (ctDNA) obtained before treatment
onset. With the protocol amendment to include cohort 2,
the ESR1 mutational status assessment was a predefined
analysis required to evaluate the primary objective of the
study. The results were blinded to patients and investigators
(Supplementary Material S2, available at https://doi.org/
10.1016/j.annonc.2020.12.013).
In addition, formalin-fixed paraffin-embedded tumour
samples were collected before study entry to genetically
identify intrinsic BC subtypes (Luminal A and B, HER2-
enriched, basal-like, and normal-like) using the HTG Edge-
Seq Oncology Biomarker Panel (Supplementary Material S3,
available at https://doi.org/10.1016/j.annonc.2020.12.013).
Objectives and endpoints
The initial primary objective was to compare PFS with pal-
bociclib plus exemestane and that with capecitabine treat-
ment. After the protocol amendment to include cohort 2,
the two new co-primary objectives were to compare PFS of
patients treated with (i) palbociclib plus fulvestrant versus
capecitabine regardless of ESR1 mutational status and (ii)
palbociclib plus ET (exemestane or fulvestrant) versus
capecitabine in patients with wild-type ESR1 in ctDNA at
study entry. PFS was defined as the time from random-
isation to the first documentation of progressive disease
based on investigators’ assessments according to RECIST
v1.1 or to death from any cause.
Secondary objectives included, among others, PFS with
palbociclib plus ET versus capecitabine regardless of ESR1
mutational status, objective response rate (ORR), clinical
benefit rate (CBR) (defined as ORR plus stable disease rate
of at least 24 weeks duration), response duration (RD), OS,
safety, and patient-reported outcomes (PROs). Concerning
PROs, we reported the time to deterioration for the global
health status from the EORTC QLQ-C30, defined as the time
from randomisation to first detection of a deterioration
event (marked with a decrease of 10 points from the
baseline).
Additionally, we explored the independent prognostic
and predictive value of intrinsic subtypes.
Statistical analysis
A total of 193 PFS events were required in cohort 2 to have
80% power to detect a difference between capecitabine
(estimated median PFS of 6 months) and palbociclib plus
fulvestrant (median PFS of 9 months4), for an HR of 0.667,
with a 5% significance level. The target sample size was











































































Figure 1. Consort diagram.
ESR1, estrogen receptor 1; WT, wild-type ESR1.
a No treatment n ¼ 2 and sample not available n ¼ 6.
b No treatment n ¼ 6 and sample not available n ¼ 11.
c Sample not available n ¼ 9.
d No treatment n ¼ 3 and sample not available n ¼ 7.
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type ESR1 and assuming an 80% ctDNA collection/detec-
tion rate and 30% of the patients with ESR1 mutations, the
required sample size was also 300 patients. The study was
designed to have two interim analyses and a final analysis.
The final PFS analysis was planned when 193 events in
cohort 2 were observed. A modification of Hochberg’s
method22 was used for two primary treatment comparisons
to provide the control of experiment-wise type 1 error rate
at a two-sided 5% significance level.
The KaplaneMeier method was used to estimate the
median PFS; 95% confidence intervals (CIs) were provided
for estimates of interest. The Cox proportional-hazards
model was used to calculate the unadjusted and adjusted
HR (aHR) (by stratification factors and number of involved
sites) and 95% CI. Efficacy analyses were based on two
populations: all randomised patients [intention-to-treat
(ITT) population] and all randomised patients with wild-
type ESR1 in ctDNA at study entry (wild-type ESR1 popu-
lation). Safety analysis was carried out on all patients who
received one or more dose of study therapy. PROs analysis
was carried out on patients with baseline and one or more4 https://doi.org/10.1016/j.annonc.2020.12.013quality of life (QoL) questionnaires completed. Time to
deterioration was analysed using Cox regression models.RESULTS
Patients and treatment
A total of 601 patients were included in this study from
March 2014 to July 2018. Cohort 1 included 296 patients
(153 on palbociclib plus exemestane and 143 on capecita-
bine) and cohort 2 included 305 patients (149 on palbociclib
plus fulvestrant and 156 on capecitabine). Efficacy analyses
included all patients, but safety analyses excluded 13 pa-
tients (10 on capecitabine and 3 on palbociclib plus ET)
never receiving study treatment. ESR1 mutations were
assessed in 557 patients (92.7%), 91% of who were from the
capecitabine arms and 94% were from the palbociclib plus
ET arms; 164 of them (29%) had ESR1 mutations (Figure 1).
All the baseline demographics and disease characteristics
were balanced between the arms across both the cohorts,
except for the number of involved sites (greater in the
capecitabine arm in cohort 2) (Table 1).Volume xxx - Issue xxx - 2021
Table 1. Patients’ baseline characteristics (intention-to-treat population)






n ¼ 153 n ¼ 143 P value n ¼ 149 n ¼ 156 P value
Demographics and disease characteristics
Median age, years (range)
60 (31-89) 60 (38-87) 0.5574 62 (38-86) 60 (33-85) 0.2618
ECOG performance statusc, n (%)
0 85 (55.6) 84 (58.7) 0.5800 90 (60.4) 93 (59.6) 0.8884
1 68 (44.4) 59 (41.3) 59 (39.6) 63 (40.4)
Visceral disease, n (%)
Yes 103 (67.3) 94 (65.7) 0.8379 97 (65.1) 102 (65.4) 0.9585
No 50 (32.7) 48 (33.6) 52 (34.9) 54 (34.6)
Most frequent disease sites, n (%)
Bone 107 (69.9) 101 (70.6) 0.8960 97 (65.1) 114 (73.1) 0.1316
Liver 67 (43.8) 61 (42.7) 0.8441 60 (40.3) 68 (43.6) 0.5569
Breast/skin/subcutaneous/lymph node 62 (40.5) 72 (50.3) 0.0896 63 (42.3) 84 (53.8) 0.0433a,b
Lung 44 (28.8) 38 (26.6) 0.6747 40 (26.8) 44 (28.2) 0.7905
Pleura 19 (12.4) 20 (14.0) 0.6903 12 (8.1) 23 (14.7) 0.0669
Number of involved sites, n (%)
1 47 (30.7) 32 (22.4) 0.2196 56 (37.6) 35 (22.4) 0.0147a
2 62 (40.5) 59 (41.3) 48 (32.2) 60 (38.5)
3 44 (28.8) 51 (35.7) 45 (30.2) 61 (39.1)
Tumour characteristics
Hormone receptor status, n (%)d
ERþ PRþ 114 (74.5) 103 (72.0) 114 (76.5) 118 (75.6)
ERþ PRe 36 (23.5) 38 (26.6) 33 (22.2) 33 (21.2)
ERe PRþ or ERþ PR not availablee 2 (1.3) 2 (1.4) 2 (1.3) 5 (3.2)
ESR1 mutational status, n (%)
Wild-type 104 (68.0) 89 (62.2) 0.8434 102 (68.5) 98 (62.8) 0.2905
Mutant 41 (26.8) 37 (25.9) 38 (25.5) 48 (30.8)
Not available 8 (5.2) 17 (11.9) 9 (6.0) 10 (6.4)
Sensitivity to prior endocrine therapy, n (%)f
Yes 107 (69.9) 104 (72.7) 0.5956 119 (79.9) 122 (78.2) 0.7218
No 46 (30.1) 39 (27.3) 30 (20.1) 34 (21.8)
Genomic subtype, n (%)g n [ 117 n [ 107 n [ 112 n [ 119
Luminal A 61 (52.1) 61 (57.0) 58 (51.8) 52 (43.7)
Luminal B 49 (41.9) 42 (39.3) 43 (38.4) 58 (48.7)
HER2-enriched 5 (4.3) 4 (3.7) 11 (9.8) 9 (7.6)
Basal-like 2 (1.7) 0 0 0
Prior therapy
Number of prior lines of endocrine therapy for MBC, n (%)
No prior endocrine therapy for MBC 30 (19.6) 31 (21.7) 38 (25.5) 44 (28.2)
1 82 (53.6) 70 (49.0) 85 (57.0) 90 (57.7)
2 35 (22.9) 34 (23.8) 12 (8.1) 9 (5.8)
3 3 (2.0) 4 (2.8) 1 (0.7) 1 (0.6)
Maintenance after chemotherapy 3 (2.0) 4 (2.8) 12 (8.1) 12 (7.7)
Prior endocrine therapy for MBC, n (%)
Aromatase inhibitor 106 (69.3) 105 (73.4) 0.4308 111 (74.5) 109 (69.9) 0.3679
Fulvestrant 44 (28.8) 35 (24.5) 0.4052 0 1 (0.6) 0.3276
Other selective estrogen receptor degrader 0 0 - 2 (1.3) 1 (0.6) 0.5350
Tamoxifen 16 (10.5) 17 (11.9) 0.6960 12 (8.1) 16 (10.3) 0.5054
Luteinising hormone-releasing hormone analogues 10 (6.5) 11 (7.7) 0.6986 8 (5.4) 14 (9.0) 0.2238
Prior chemotherapy for MBC, n (%)
Yes 48 (31.4) 41 (28.7) 0.6125 41 (27.5) 41 (26.3) 0.8079
No 105 (68.6) 102 (71.3) 108 (72.5) 115 (73.7)
Line at study entry,h n (%)
1st line 27 (17.6) 31 (21.7) 0.5498 38 (25.5) 43 (27.6) 0.8477
2nd line 61 (39.9) 50 (35.0) 76 (51.0) 79 (50.6)
3rd line 62 (40.5) 62 (43.3) 35 (23.5) 34 (21.8)
Continued
M. Martin et al. Annals of Oncology
Volume xxx - Issue xxx - 2021 https://doi.org/10.1016/j.annonc.2020.12.013 5
Table 1. Continued






n ¼ 153 n ¼ 143 P value n ¼ 149 n ¼ 156 P value
Status at initial diagnosis, n (%)
M0 127 (83.0) 109 (76.2) 0.1469 115 (77.2) 120 (76.0) 0.9573
M1 (de novo MBC) 26 (17.0) 34 (23.8) 34 (22.8) 36 (23.1)
P value statistically significant.
ER, estrogen receptor; ESR1, estrogen receptor 1; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; Lum, luminal; MBC, metastatic breast cancer; PR,
progesterone receptor.
a No significant differences in patients’ baseline characteristics were identified between treatment groups, except for the number of involved sites and breast/skin/subcutaneous/
lymph node disease site in cohort 2.
b Hazard ratios were not adjusted by ‘breast/skin/subcutaneous/lymph node’ as disease site, because this item is included within stratification factor (visceral versus non-visceral).
c Eastern Cooperative Oncology Group (ECOG) performance status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating greater disability.
d Based on local laboratory determination, positive defined as 1% positive cells by immunohistochemistry for ER and/or PR. Hormone receptor status was evaluated on primary
tumours in 62.1% of patients and on metastatic lesions in 37.9% of them.
e One patient treated with exemestane þ palbociclib was triple-negative (protocol deviation).
f Sensitivity to prior endocrine therapy was defined as relapse after 24 months of adjuvant ET or response (complete or partial) or stabilisation after 24 weeks of the most recent
ET in the context of advanced disease.
g By HTG EdgeSeq Oncology Biomarker Panel.
h Line at study entry means the treatment line received in the study, considering all prior lines of therapy, either chemotherapy and/or endocrine therapy.
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2019), 80 patients were still on the study treatment: 10
(6.7%) were on palbociclib plus exemestane, 37 (24.8%) on
palbociclib plus fulvestrant, and 33 (11%) on capecitabine.
The median relative dose-intensity in cohort 1 was 82.6%
for capecitabine, 100% for exemestane, and 95.2% for pal-
bociclib, and that in cohort 2 was 79.5% for capecitabine,
100% for fulvestrant, and 92.9% for palbociclib. The median
time on study therapy in cohort 1 was higher for capeci-
tabine, 7.9 months (range: 0.2-50.5), than for palbociclib
plus exemestane, 6.3 months (range: 0.5-52.3). However, in
cohort 2 the median time on study therapy was 6.3 months
for capecitabine (range: 0.2-26.4) and 7.8 months for pal-
bociclib plus fulvestrant (range: 0.8-31.1). The main reason
for permanent discontinuation of the treatment was dis-
ease progression. In both cohorts, the proportion of pa-
tients who discontinued due to progressive disease was
smaller in the capecitabine arm (65.7% in cohort 1, 58.6% in
cohort 2) than in the palbociclib plus exemestane (81.3%)
and palbociclib plus fulvestrant arms (68.5% in cohort 2)
(Supplementary Table S1, available at https://doi.org/10.
1016/j.annonc.2020.12.013).Efficacy
The median follow-ups of cohort 2 and the wild-type ESR1
population were 13.5 months (range: 0.0-30.7) and 18.9
months (range: 0.0-56.3), respectively. The median PFS in
cohort 2 was 7.5 months (95% CI: 5.7-10.9) in the palbo-
ciclib plus fulvestrant arm and 10.0 months (95% CI: 6.3-
12.9) in the capecitabine arm (aHR: 1.13; 95% CI: 0.85-1.50;
P ¼ 0.398). The median PFS in the wild-type ESR1 popula-
tion was 8.0 months (95% CI: 6.5-10.9) in the palbociclib
plus ET arm and 10.6 months (95% CI: 7.4-13.0) in the
capecitabine arm (aHR: 1.11; 95% CI: 0.87-1.41; P ¼ 0.404)
(Figure 2). PFS subgroup analyses by stratification factors
and other baseline characteristics in cohort 2 and in the6 https://doi.org/10.1016/j.annonc.2020.12.013wild-type ESR1 population (Figure 3), as well as in the
overall population regardless of ESR1 mutational status
(Supplementary Figure S1, available at https://doi.org/10.
1016/j.annonc.2020.12.013) confirmed the non-superiority
of palbociclib plus ET over capecitabine.
Regarding the study’s secondary endpoints of efficacy,
the median PFS in all patients from cohort 1 and cohort 2
was 7.4 months (95% CI: 5.9-9.3) in the palbociclib plus ET
arm and 9.4 months (95% CI: 7.5-11.3) in the capecitabine
arm (aHR: 1.11; 95% CI: 0.92-1.34; P ¼ 0.380)
(Supplementary Figure S2, available at https://doi.org/10.
1016/j.annonc.2020.12.013). The aHR for PFS in the
mutant ESR1 population was 1.12 (95% CI: 0.78-1.60; P ¼
0.540) as shown in Supplementary Figure S3, available at
https://doi.org/10.1016/j.annonc.2020.12.013. The ORR in
cohort 2 was 26.7% for palbociclib plus fulvestrant versus
33.3% for capecitabine. In patients with ESR1 wild-type,
ORR was 27.8% for palbociclib plus ET versus 36.9% for
capecitabine. The CBR was very similar between the arms in
cohort 2 and the patients with ESR1 wild-type. The median
RD in cohort 2 was 9.4 months in the palbociclib plus ful-
vestrant arm and 12.9 months in the capecitabine arm (HR:
0.69; 95% CI: 0.33-1.46; P ¼ 0.335). Finally, the median RD
in the wild-type ESR1 population was 9.7 months in the
palbociclib plus ET arm and 11.2 months in the capecitabine
arm (HR: 0.75; 95% CI: 0.44-1.25; P ¼ 0.269)
(Supplementary Table S2, available at https://doi.org/10.
1016/j.annonc.2020.12.013).PROs
The completion rate of the questionnaires was similar
across the arms, surpassing 82% until cycle 13. The median
time to deterioration in global health status was 8.6 months
in patients treated with palbociclib plus ET versus 6.2
months in those treated with capecitabine (aHR: 0.67, 95%
CI: 0.53-0.85; P ¼ 0.001) (Figure 4).Volume xxx - Issue xxx - 2021
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Adjusted hazard ratio (95% CI): 1.11 (0.87-1.41), P = 0.404
Figure 2. Progression-free survival.
KaplaneMeier curves for PFS were represented for (A) patients in cohort 2: palbociclib plus fulvestrant versus capecitabine and (B) patients with wild-type ESR1 from
cohort 1 þ cohort 2: palbociclib plus endocrine therapy versus capecitabine. Hazard ratios were adjusted by disease site, prior sensitivity to endocrine therapy, prior
chemotherapy for metastatic breast cancer, and the number of involved sites.
CI, confidence interval; ESR1, estrogen receptor 1; ET, endocrine therapy; fulve, fulvestrant; No, number; Palbo, palbociclib; PFS, progression-free survival.
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Safety information is shown in Table 2 and Supplementary
Table S3, available at https://doi.org/10.1016/j.annonc.
2020.12.013. The most frequent grade 3-4 toxicities in the
palbociclib plus exemestane, palbociclib plus fulvestrant,
and capecitabine arms, were neutropenia [(57.4%, 55.7%,
5.5%, respectively) with febrile neutropenia (1.3%, 0.7%,Volume xxx - Issue xxx - 20211.4%, respectively)], hand/foot syndrome (0%, 0%, 23.5%,
respectively), diarrhoea (1.3%, 1.3%, 7.6%, respectively),
fatigue (1.3%, 0.7%, 5.5%, respectively), and anaemia (0.7%,
2.0%, 3.5%, respectively). The incidence of non-
haematologic toxicity grade 3 was higher for patients on
capecitabine (38.8%) than for those on palbociclib plus
exemestane (6.7%) or palbociclib plus fulvestrant (6.0%).
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Palbociclib + fulvestrant better Capecitabine better
P valuea
P valueb
Figure 3. Forest plot of progression-free survival hazard ratios by subgroups.
Subgroups for progression-free survival and their respective hazard ratios were represented for (A) patients in cohort 2: palbociclib plus fulvestrant versus capecitabine
and (B) patients with wild-type ESR1 from cohort 1 þ cohort 2: palbociclib plus endocrine therapy versus capecitabine. P values from ManneWhitney test (continuous
variables) and chi-square test (categorical variables).
CI, confidence interval; CT, chemotherapy; ESR1, estrogen receptor 1; ET, endocrine therapy; MBC, metastatic breast cancer; ALL, all patients of Cohort 2 (Figure A) all
patients Wild-Type ESR1 (Cohort 1 + cohort 2) (Figure B).
a Unadjusted Cox P value comparing palbociclib plus fulvestrant versus capecitabine in each subgroup.
b Unadjusted Cox P value comparing palbociclib plus endocrine therapy versus capecitabine in each subgroup.
Annals of Oncology M. Martin et al.patients on palbociclib plus ET as opposed to 3.8% of the
patients on capecitabine.
Serious AEs related to the study treatment were reported
by 10.4% of the patients on capecitabine, 4.0% of the pa-
tients on palbociclib plus exemestane, and 3.4% of the
patients on palbociclib plus fulvestrant.8 https://doi.org/10.1016/j.annonc.2020.12.013A total of 46 patients on capecitabine (15.9%) dropped
out due to AEs compared with 9 patients (6%) on palboci-
clib plus exemestane and 10 patients (6.7%) on palbociclib
plus fulvestrant.
Of the 17 deaths observed during the study treatment,
11 were due to progressive disease; two serious AEsVolume xxx - Issue xxx - 2021
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Figure 4. Time to deterioration based on EORTC core quality-of-life-C30_global health status.
The figure shows the median time to deterioration for the global health status from the European Organization for Research and Treatment of Cancer core quality-of-
life-C30 (EORTC QLQ-C30). The adjusted hazard ratio was obtained using a stratified Cox proportional hazard model with treatment arm, the stratification factors
(visceral, sensitivity to prior ET, prior CT for MBC), and number of involved sites as covariates.
CI, confidence interval; CT, chemotherapy; EORTC, European Organization for Research and Treatment of Cancer; ET, endocrine therapy; MBC, metastatic breast cancer;
No., number; Palbo, palbociclib; TTD, time to deterioration.
M. Martin et al. Annals of Oncologyoccurred while patients were on palbociclib plus ET
(pneumonitis and sepsis), and four occurred while the pa-
tients were on capecitabine (diarrhoea, general health sta-
tus worsening, colitis, and sudden death). Diarrhoea,
general health status worsening, and colitis were consid-
ered toxic deaths according to the investigators’
assessments.Exploratory objectives
Prognostic/predictive value of intrinsic BC subtypes. Sub-
types were obtained for 455 patients (94.4% of the 482
patients assessed) with metastatic (30%) or primary tumour
tissue (70%) available (Table 1); 75.7% of cohort 2 and
79.6% of the wild-type ESR1 patient population. Most pa-
tients (93.2%) had luminal tumours. Cohort 2 patients with
luminal tumours showed a median PFS of 7.7 and 10
months with palbociclib plus fulvestrant and capecitabine,
respectively (HR: 1.07; 95% CI: 0.77-1.49; P ¼ 0.681). Pa-
tients with non-luminal tumours (n ¼ 20) had a median PFS
of 3.3 and 13.7 months with palbociclib plus fulvestrant and
capecitabine, respectively (HR: 5.87; 95% CI: 1.60-21.55;
P ¼ 0.008). Patients with wild-type ESR1 luminal tumours
presented a median PFS of 9.3 and 11.0 months with pal-
bociclib plus fulvestrant and capecitabine, respectively (HR:
1.01; 95% CI: 0.77-1.33; P ¼ 0.930). Patients with non-
luminal tumours (n ¼ 25) on palbociclib plus ET and
capecitabine had a median PFS of 2.3 and 13.7 months,Volume xxx - Issue xxx - 2021respectively (HR: 7.36; 95% CI: 2.05-26.37; P ¼ 0.002)
(Supplementary Figure S4, available at https://doi.org/10.
1016/j.annonc.2020.12.013).DISCUSSION
The PEARL trial did not provide evidence of PFS superiority
of palbociclib plus fulvestrant or of palbociclib plus ET in
patients without ESR1 mutations over capecitabine in AI-
resistant MBC patients. However, it is worth noting that
compared with capecitabine, palbociclib plus ET was asso-
ciated with a significant delay in QoL deterioration, less
treatment discontinuations due to AEs, and a lower pro-
portion of patients with related serious AEs.
The initial study design of the PEARL trial was modified
after some compelling evidence that ESR1 mutations (pre-
sent in up to 37% of patients pretreated with AIs) could
produce resistance to additional AI therapy, but not to
fulvestrant.15-17 Since in the initial design the endocrine arm
was exemestane plus palbociclib, we added a second cohort
of patients in which the endocrine arm was fulvestrant plus
palbociclib, to avoid the potential negative influence of
ESR1 mutations in patients treated with AIs. In fact, we
identified 29% of ESR1 mutations in the patients included in
this trial. Of note, this modification was made before any
results were available.
The combination of palbociclib plus fulvestrant has been
approved by several regulatory agencies for the treatmenthttps://doi.org/10.1016/j.annonc.2020.12.013 9








n ¼ 150 n ¼ 149 n ¼ 289
Adverse events according to
NCI-CTCAE version 4.0, n (%)
147 (98.0) 148 (99.3) 286 (99.0)
Related 133 (88.7) 128 (85.9) 275 (95.2)
Leading to study treatment
discontinuation
9 (6.0) 10 (6.7) 46 (15.9)
Most frequent related adverse events of grade ‡3 according to NCI-CTCAE
version 4.0
Neutropenia 86 (57.4) 83 (55.7) 16 (5.5)
Febrile neutropenia 2 (1.3) 1 (0.7) 4 (1.4)
Hand/foot syndrome 0 0 68 (23.5)
Diarrhoea 2 (1.3) 2 (1.3) 22 (7.6)
Fatigue 2 (1.3) 1 (0.7) 16 (5.5)
Anaemia 1 (0.7) 3 (2.0) 10 (3.5)
Serious adverse events, n (%) 24 (16.0) 19 (12.8) 63 (21.8)
Related 6 (4.0) 5 (3.4) 30 (10.4)
Leading to study drug
discontinuation
5 (3.3) 2 (1.3) 12 (4.2)
On study treatment deathsb,
n (%)
5 (3.3) 5 (3.4) 7 (2.4)
Related to breast cancer 4 (2.7) 4 (2.7) 3 (1.0)
Other 1c (0.7) 1d (0.7) 4e (1.4)
Bold indicates the higher differences between treatment arms.
a Adverse events were coded according to the National Cancer Institute-Common
Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0.
b On-study treatment death is defined as the death that occurs in the period
between the first dose of the study treatment and 30 days after the last dose.
c Pneumonitis.
d Sepsis.
e Sudden death, diarrhoea, general health status worsening, and colitis (these last
three were considered toxic deaths according to the investigators’ assessments).
Annals of Oncology M. Martin et al.of patients with hormone receptor-positive/HER2-negative
AI-resistant MBC based on the PALOMA-3 trial’s results,
which clearly showed the efficacy of palbociclib in delaying
resistance to fulvestrant. However, it did not provide in-
formation on the potential benefit of palbociclib plus ful-
vestrant with respect to other available therapeutic options
(i.e. everolimus plus ET or chemotherapy) in this specific
patient population. Given the poor performance of the
fulvestrant-placebo arm in the PALOMA-3 trial (median PFS:
4.6 months), many oncologists might prefer other alterna-
tives. The PEARL trial included patients with relatively
similar characteristics to those in the PALOMA-3 trial;
however, the median PFS of ET plus palbociclib in the PEARL
trial was somewhat lower. The most plausible explanation
for this apparent discrepancy is the different characteristics
of the population included in these two trials, with the
patients in PEARL having a worse prognosis. Other studies
exploring the combination of ET with CDK4/6 inhibitors as
second-line therapy showed better results with a median
PFS of 16.4 months in the MONARCH-26 and 25.3 months in
the MONALEESA-35 trials. However, these data are not
comparable with those of the PEARL study because the
populations are quite different. For instance, only one prior
line of ET was permitted and prior chemotherapy for MBC
was not allowed in the MONARCH-2 and MONALEESA-3
studies, while there were no such limitations in the PEARL
trial.10 https://doi.org/10.1016/j.annonc.2020.12.013Considering the limited efficacy of palbociclib plus ET in
this patient population (8- and 9.5-month PFS in the
PEARL and PALOMA-3 trials, respectively), the high effi-
cacy of the combination of ET and CDK 4/6 inhibitors in AI-
sensitive MBC patients (with median PFS of around 2
years), and the demonstration of OS benefit in the only
first-line trial that has reported this outcome so far,9 the
findings in the PEARL trial indirectly suggest that palbo-
ciclib combinations are less effective in pretreated MBC
patients and should be used earlier in the treatment
timeline, while capecitabine can be left for later lines. This
statement agrees with the results from the meta-analysis
by Giuliano et al.23 This analysis showed that no chemo-
therapy regimen was significantly better than CDK4/6 in-
hibitors plus hormone therapies in the first- or second-line
setting, supporting the treatment guideline recommen-
dations for the use of ET plus targeted agents in earlier
lines of treatment in women with hormone receptor-
positive/HER2-negative MBC.
In addition, while the PEARL trial did not meet its co-
primary objectives, it still provides evidence and sugges-
tions for the management of hormone receptor-positive
AI-resistant MBC. While patients’ PFS with capecitabine
and palbociclib plus ET were similar, toxicity with capecita-
bine was higher, and patients had earlier QoL deterioration
with this chemotherapy. Thus, the endocrine combination
could be the best choice for these patients. Capecitabine,
albeit having higher AEs, remains an appropriate alternative
where health care costs are restricted.
Efficacy results of the PEARL study were consistent across
patient subgroups except for the small proportion of pa-
tients with genetically defined non-luminal tumours, for
which capecitabine was associated with a significantly bet-
ter PFS. However, these results should be interpreted with
caution and further validated in independent cohorts,
because the non-luminal population represented only 5.2%
of the patients in the PEARL trial.
Potential limitations of the study are: (i) the capecitabine
outcome was better than that initially anticipated (9
months compared with 6 months in the protocol assump-
tions); (ii) the open-label study design may lead to biased
interpretations, e.g. more patients were censored before
initiating the study treatment in the capecitabine arm than
in the palbociclib plus ET arm (3.3% and 1.0%, respectively);
(iii) the subtype classification for the exploratory objective
was carried out in 70% of patients in the primary tumour,
which might have changed in the metastatic disease in a
proportion of patients. Finally, there are several strengths of
the PEARL study that should be considered: (i) this is a well
conducted academic, multicentre, international trial; (ii) the
sample size with 601 patients is high; (iii) the prospective
collection of plasma samples to assess ESR1 mutations was
conducted.
In conclusion, palbociclib plus ET did not improve PFS
compared with capecitabine in patients with AI-resistant
MBC; however, it was better tolerated and showed
improved QoL.Volume xxx - Issue xxx - 2021
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